Not Signed In - MAP Pharmaceuticals Initiates Phase 2 Clinical Trial In Patients With Migraine
Wed, 06 Sep 2006 07:00 AM EST
... MAP Pharmaceuticalsannounced today the initiation and first patient dosing of a Phase 2clinical trial evaluating MAP0004 for the treatment of acute migraineheadaches. MAP0004 is a novel inhaled drug formulation of dihydroergotaminemesylate (DHE) administered with MAP's patented Tempo(TM) Inhaler. [click link for full article] ...
Related Topics
- Clinical Trials
- Migraine
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Eletriptan
- Tarceva
- Headache
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Clinical Growth Charts
- Reflexology
- Bevacizumab Injection
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Crohn's Disease
- Pancreatic Cancer
- Phenylephrine Eye Solution
- Smoking Cessation and Continued Risk in Cancer Patients
email this page
print this page
bookmark this page
feedback on this page
